Akèy › Kansè ovè › Indiana › Indianapolis
Etid klinik pou Kansè ovè nan Indianapolis, IN
17 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Indianapolis (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- IU Simon Cancer Center, Indianapolis
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Ap rekriteFaz 2
- Indiana University Melvin and Bren Simon Cancer Center /ID# 275492, Indianapolis
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ap rekriteFaz 2
- Site 0284 - Community Cancer Center North, Indianapolis
- Site 0217 - St Vincent Hospital and Health Care Centers, Indianapolis
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- Indiana University (IU) School of Medicine, Indianapolis
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Community Health Network, Indianapolis
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Ap rekriteFaz 3
- Franciscan Health Indianapolis ( Site 0081), Indianapolis
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Ap rekriteFaz 3
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Ap rekriteFaz 1
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- Riley Hospital for Children, Indianapolis
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Ap rekriteFaz 1
- Indiana University, Indianapolis
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ap rekrite
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
- ak 1 plis
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Community Health Network, Indianapolis
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Ap rekriteFaz 2/3
- Community Health Network - MD Anderson, Indianapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network Investigational Drug Services, Indianapolis
- ak 1 plis
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Ap rekriteFaz 3
- Indiana University, Indianapolis
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
Lòt etid nan Indianapolis
- Kansè Poumon ki pa ti selil32 etid
- Kansè (tout kalite)24 etid
- Ensifizyans kadyak23 etid
- Obèsite20 etid
- Kansè nan tete20 etid
- Kansè Metastatik19 etid
- Kansè kolorektal18 etid
- Maladi kadyovaskilè17 etid
- Kansè poumon16 etid
- Dyabèt tip 114 etid
- Kansè Endomèt14 etid
- Maladi Alzheimer14 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.